Arbutus Biopharma Corporation2025财年第一财季实现净利润-24.53百万美元，同比减少37.19%

市场透视2025-05-23

5月23日，Arbutus Biopharma Corporation（ABUS.US）公布财报，公告显示公司2025财年第一财季净利润为-24.53百万美元，同比减少37.19%；其中营业收入为1.76百万美元，同比增加15.03%，每股基本收益为-0.13美元。从资产负债表来看，Arbutus Biopharma Corporation（ABUS.US）总负债37.85百万美元，其中短期债务...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537192319?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2537192319","market":"us","top_or_hot":-1,"title":"Arbutus Biopharma Corporation2025财年第一财季实现净利润-24.53百万美元，同比减少37.19%","media":"市场透视","content":"<div>\n<p>5月23日，Arbutus Biopharma Corporation（ABUS.US）公布财报，公告显示公司2025财年第一财季净利润为-24.53百万美元，同比减少37.19%；其中营业收入为1.76百万美元，同比增加15.03%，每股基本收益为-0.13美元。从资产负债表来看，Arbutus Biopharma Corporation（ABUS.US）总负债37.85百万美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000054a488765e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arbutus Biopharma Corporation2025财年第一财季实现净利润-24.53百万美元，同比减少37.19%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArbutus Biopharma Corporation2025财年第一财季实现净利润-24.53百万美元，同比减少37.19%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000054a488765e&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月23日，Arbutus Biopharma Corporation（ABUS.US）公布财报，公告显示公司2025财年第一财季净利润为-24.53百万美元，同比减少37.19%；其中营业收入为1.76百万美元，同比增加15.03%，每股基本收益为-0.13美元。从资产负债表来看，Arbutus Biopharma Corporation（ABUS.US）总负债37.85百万美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000054a488765e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABUS","symbol_name":"Arbutus Biopharma Corporation","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000054a488765e&s=b","article_id":"2537192319","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000054a488765e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2537192319","pubTimestamp":1747929628,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月23日，Arbutus Biopharma Corporation公布财报，公告显示公司2025财年第一财季净利润为-24.53百万美元，同比减少37.19%；其中营业收入为1.76百万美元，同比增加15.03%，每股基本收益为-0.13美元。从资产负债表来看，Arbutus Biopharma Corporation总负债37.85百万美元，其中短期债务563000.00美元，资产负债比为0.04，流动比率为0.07。机构评级：截至2025年5月23日，当前有4家机构对Arbutus Biopharma Corporation目标价做出预测，其中目标均价为5.25美元，其中最低目标价为4.00美元，最高目标价为7.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ABUS":"Arbutus Biopharma Corporation"},"translate_title":"Arbutus Biopharma Corporation achieved net profit of-US $24.53 million in the first fiscal quarter of fiscal year 2025, a year-on-year decrease of 37.19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":1},"content_text":"5月23日，Arbutus Biopharma Corporation（ABUS.US）公布财报，公告显示公司2025财年第一财季净利润为-24.53百万美元，同比减少37.19%；其中营业收入为1.76百万美元，同比增加15.03%，每股基本收益为-0.13美元。从资产负债表来看，Arbutus Biopharma Corporation（ABUS.US）总负债37.85百万美元，其中短期债务563000.00美元，资产负债比为0.04，流动比率为0.07。机构评级：截至2025年5月23日，当前有4家机构对Arbutus Biopharma Corporation目标价做出预测，其中目标均价为5.25美元，其中最低目标价为4.00美元，最高目标价为7.00美元。公司简介：Arbutus Biopharma Corp 是一家专注于传染病的临床阶段生物制药公司。该公司正在利用其广泛的病毒学专业知识来识别和开发具有不同作用机制的新型疗法，这些疗法可以结合起来为慢性乙型肝炎病毒 （cHBV） 患者提供功能性治愈。其内部开发的专有化合物管道包括 RNAi 治疗药物 imdusiran （AB-729） 和口服 PD-L1 抑制剂 AB-101。此外，该公司还专注于最大限度地利用其内部开发的脂质纳米颗粒 （LNP） 递送技术的机会。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537192319","isCrawlerRequest":true}